Ligand Reports First Quarter 2022 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/15/2026
- Wall St futures tick up as investors weigh earnings; PayPal jumps
- PayPal rallies 20% on report Stripe, Advent made $53 billion bid
- Oil prices rise 1% as hostilities worsen in the Middle East
- ASML capacity upgrade soothes AI chip bottleneck fears
- Dollar steadies as Middle East escalation counters soft US inflation
- IBM misses Q2 targets as mainframe and software sales disappoint
- Verizon planning new round of layoffs this week - Barron’s
- Kosovo bans Serb minister over ethnic cleansing remarks
- Lucid Group shares quickly cut in half on report of potential bankruptcy
- S&P 500 and Nasdaq end higher on cool inflation data, solid bank earnings
Ligand Pharma (LGND) Tops Q1 EPS by 10c
May 4, 2022 4:43 PM EDTLigand Pharma (NASDAQ: LGND) reported Q1 EPS of $0.76, $0.10 better than the analyst estimate of $0.66. Revenue for the quarter came in at $45.7 million versus the consensus estimate of $34.21 million.
GUIDANCE:
Ligand is reaffirming 2022 revenue guidance for the combined business and providing revenue estimated to be attributable to the OmniAb... More
